Open

Pediatric Ravulizumab Study

To test the effectiveness and safety of the drug ravulizumab in patients aged 6-18 years.

Age & Gender

6 years ~ 17 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

Participant will asked questions about their MG and how it affects activities of daily living; in addition Parents/legal guardians will be asked about changes in medications. Blood will be drawn at every visit and study drug will be administered via IV line

Incentives

Gas mileage , hotel stay for out of town patients and meals

In-person visits:
30

Phone or online visits:
3

Total length of participation:
134 weeks

Looking for Specific Volunteers

Able to participate:

Generalized myasthenia Gravis
AChR antibody positive status

Not eligible if:

Pregnancy
other autoimmune conditions

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

James Howard
Neurology-Neuromuscular

Study Type

Clinical or Medical
Interventional

Study Topics

Bones, Joints, Muscles
Chronic Conditions

IRB Number

23-2163

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.